Penile cancer · 6 regimens
Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Panitumumab monotherapy Variant #01 | — | R 25 254 | 14d | ~1.8 mo | ~10.2 mo | ~2 | ~R 50 508 PFS proxy · indirect | 3 |
PCF Variant #01 | — | R 2 300 | — | — | — | ~3 | ~R 6 899 indirect | — |
Cisplatin and Irinotecan (IC) Variant #01 | — | R 1 795 | 21d | ~3.8 mo | ~12.9 mo | ~5 | ~R 8 977 PFS proxy · indirect | 10 |
Cisplatin and Fluorouracil (CF) Variant #01 | — | R 1 783 | 28d | ~5.6 mo | ~11.1 mo | ~3 | ~R 5 350 PFS proxy · indirect | 38 |
Paclitaxel monotherapy Variant #02 | — | R 734 | 28d | — | ~8.9 mo | ~7 | ~R 5 141 PFS proxy · indirect | 4 |
BMP Variant #01 Partial | — | R 551 | 28d | — | — | ~11 | ~R 6 063 indirect | — |
6 of 6 regimens shown